Clearline Capital LP Increases Stock Position in Heron Therapeutics, Inc. $HRTX

Clearline Capital LP boosted its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 26.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,235,239 shares of the biotechnology company’s stock after purchasing an additional 2,522,712 shares during the quarter. Heron Therapeutics comprises approximately 0.8% of Clearline Capital LP’s holdings, making the stock its 26th largest holding. Clearline Capital LP owned 6.67% of Heron Therapeutics worth $15,906,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. PKS Advisory Services LLC purchased a new stake in Heron Therapeutics in the 3rd quarter worth $25,000. Advisory Services Network LLC lifted its stake in Heron Therapeutics by 2,383.4% in the 4th quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 18,114 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new stake in Heron Therapeutics in the 2nd quarter worth $26,000. Jones Financial Companies Lllp lifted its stake in Heron Therapeutics by 5,541.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 23,661 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in Heron Therapeutics by 39.1% in the 4th quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 6,858 shares in the last quarter. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on HRTX. Needham & Company LLC cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research cut shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. Finally, HC Wainwright reduced their target price on shares of Heron Therapeutics to $2.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $2.50.

Heron Therapeutics Stock Performance

Heron Therapeutics stock opened at $0.39 on Thursday. The company’s 50-day moving average price is $0.85 and its 200-day moving average price is $1.07. Heron Therapeutics, Inc. has a twelve month low of $0.38 and a twelve month high of $2.30. The company has a quick ratio of 1.51, a current ratio of 2.53 and a debt-to-equity ratio of 17.51. The company has a market cap of $73.31 million, a PE ratio of -2.15 and a beta of 1.58.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, May 11th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.The business had revenue of $34.71 million during the quarter, compared to the consensus estimate of $36.72 million. On average, equities research analysts forecast that Heron Therapeutics, Inc. will post -0.09 EPS for the current fiscal year.

Heron Therapeutics Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.